β -Elemene inhibits cell proliferation by regulating the expression and activity of topoisomerases i and II α in human hepatocarcinoma HepG-2 cells

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Gong, Min ^a   Liu, Ying ^a   Zhang, Jian ^a   Gao, Ya Jie ^a   Zhai, Ping Ping ^a   Su, Xi ^a   Li, Xiang ^a   Li, Yan ^a   Hou, Li ^a   Cui, Xiao Nan ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ELEMENE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE II ALPHA; KINETOPLAST DNA; UNCLASSIFIED DRUG; BETA-ELEMENE; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); SESQUITERPENE; TUMOR ANTIGEN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; DNA STRAND BREAKAGE; DOSE TIME EFFECT RELATION; FLOW CYTOMETRY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN EXPRESSION; REGULATORY MECHANISM; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY;

ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; SESQUITERPENES;

EID: 84937010875     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/153987     Document Type: Article

References (23)

1. R. Lencioni, X.-P. Chen, L. Dagher, and A. P. Venook, "Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?" The Oncologist, vol. 15, supplement 4, pp. 42-52, 2010.
2. B. H. O'Neil and A. P. Venook, "Hepatocellular carcinoma: the role of the North American GI steering committee hepatobiliary task force and the advent of effective drug therapy," The Oncologist, vol. 12, no. 12, pp. 1425-1432, 2007.
3. P.Merle and F.Mornex, "Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma," Cancer/ Radiotherapie, vol. 15, no. 1, pp. 69-71, 2011.
4. J. Song, H. Xu, J. Tang, X. Li, and S. Zhou, "Transcatheter hepatic arterial infusion chemotherapy combined with element emulsion for treatment of primary hepatic carcinoma," China Pharmaceuticals, vol. 16, no. 16, pp. 23-24, 2007.
5. Q. Q. Li, R.X. Lee, H. Liang, and Y. Zhong, "Anticancer activity of β-elemene and its synthetic analogs in human malignant brain tumor cells," Anticancer Research, vol. 33, no. 1, pp. 65-76, 2013.
6. B. Zou, Q. Q. Li, J. Zhao, J. M. Li, C. F. Cuff, and E. Reed, "β-elemeneand taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells," Anticancer Research, vol. 33, no. 3, pp. 929-940, 2013.
7. X.-W. Xu, Z.-Z. Yuan, W.-H. Hu, and X.-K. Wang, "Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of non-small cell lung cancer," Zhongguo Zhongyao Zazhi, vol. 38, no. 9, pp. 1430-1437, 2013.
8. J. Hu, W. Jin, and P.-M. Yang, "Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by β-elemene," Chinese Journal of Oncology, vol. 26, no. 5, pp. 268-270, 2004.
9. W. Wu, K. Liu, and X. Tang, "Preliminary study on the antitumor immuno-protective mechanism of β-elemene," Chinese Journal of Oncology, vol. 21, no. 6, pp. 405-408, 1999.
10. X. Li, G. Wang, J. Zhao et al., "Antiproliferative effect of β-elemenein chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase," Cellular and Molecular Life Sciences, vol. 62, no. 7-8, pp. 894-904, 2005.
11. X. S. Wu, T. Xie, J. Lin et al., "An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas," Journal of Pharmacy and Pharmacology, vol. 61, no. 12, pp. 1653-1656, 2009.
12. W. D. Figg, P. Arlen, J. Gulley et al., "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen independent prostate cancer," Seminars in Oncology, vol. 28, supplement 15, no. 4, pp. 62-66, 2001.
13. Y. Sun, L. J. Shan, Y. J. Liu, and X.N. Cui, "The effect of cinobufacini injection on DNA topoisomerase I of human hepatocellular carcinomaHepG-2 cells," Chinese Journal of Oncology, vol. 19, no. 6, pp. 410-413, 2010.
14. S. Belluti, V. Basile, P. Benatti, E. Ferrari, G. Marverti, and C. Imbriano, "Concurrent inhibition of enzymatic activity andNFY-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells," Cell Death and Disease, vol. 4, no. 8, article e756, 2013.
15. D. Perrin, B. van Hille, J.-M. Barret et al., "F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action," Biochemical Pharmacology, vol. 59, no. 7, pp. 807-819, 2000.
16. W. A. Denny and B. C. Baguley, "Dual topoisomerase I/II inhibitors in cancer therapy," Current Topics in Medicinal Chemistry, vol. 3, no. 3, pp. 339-353, 2003.
17. W. Fayad, M. Fryknäs, S. Brnjic, M. H. Olofsson, R. Larsson, and S. Linder, "Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters," PLoS ONE, vol. 4, no. 10, Article IDe7238, 2009.
18. S. Squires, A. J. Ryan, H. L. Strutt, P. J. Smith, and R. T. Johnson, "Deoxyguanosine enhances the cytotoxicity of the topoisomerase I inhibitor camptothecin by reducing the repair of double-strand breaks induced in replicating DNA," Journal of Cell Science, vol. 100, no. 4, pp. 883-893, 1991.
19. X. Huang, H. D. Halicka, F. Traganos, T. Tanaka, A. Kurose, and Z. Darzynkiewicz, "Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis," Cell Proliferation, vol. 38, no. 4, pp. 223-243, 2005.
20. Q. Q. Li, G. Wang, M. Zhang, C. F. Cuff, L. Huang, and E. Reed, "β-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis," Oncology Reports, vol. 22, no. 1, pp. 161-170, 2009.
21. G. del Bino, J. S. Skierski, and Z. Darzynkiewicz, "Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells," Cancer Research, vol. 50, no. 18, pp. 5746-5750, 1990.
22. W. Gorczyca, J. Gong, B. Ardelt, F. Traganos, and Z. Darzynkiewicz, "The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents," Cancer Research, vol. 53, no. 13, pp. 3186-3192, 1993.
23. O. Sordet, Q. A. Khan, and Y. Pommier, "Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction," Cell Cycle, vol. 3, no. 9, pp. 10951097, 2004.